$9.64
2.08% today
NYSE, Sep 24, 07:15 pm CET
ISIN
US03168L1052
Symbol
AMRX

Amneal Pharmaceuticals, Inc. Class A Stock price

$9.84
+0.56 6.03% 1M
+0.95 10.69% 6M
+1.92 24.24% YTD
+1.32 15.49% 1Y
+7.74 368.57% 3Y
+5.83 145.39% 5Y
-30.64 75.69% 10Y
+5.17 110.71% 20Y
NYSE, Closing price Tue, Sep 23 2025
-0.16 1.60%
ISIN
US03168L1052
Symbol
AMRX
Industry

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$5.5b
Net debt
$2.5b
Cash
$71.5m
Shares outstanding
314.0m
Valuation (TTM | estimate)
P/E
984.0 | 13.0
P/S
1.1 | 1.0
EV/Sales
1.9 | 1.8
EV/FCF
21.2
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
107.0%
ROCE
16.4%
ROIC
9.2%
Debt/Equity
-22.5
Financials (TTM | estimate)
Revenue
$2.9b | $3.1b
EBITDA
$625.2m | $680.1m
EBIT
$379.8m | $574.4m
Net Income
$3.4m | $238.6m
Free Cash Flow
$261.6m
Growth (TTM | estimate)
Revenue
47.2% | 9.6%
EBITDA
40.9% | 16.3%
EBIT
73.9% | 64.9%
Net Income
104.1% | 304.2%
Free Cash Flow
48.6%
Margin (TTM | estimate)
Gross
37.7%
EBITDA
21.9% | 22.2%
EBIT
13.3%
Net
0.1% | 7.8%
Free Cash Flow
9.2%
More
EPS
$0.0
FCF per Share
$0.8
Short interest
2.5%
Employees
8k
Rev per Employee
$340.0k
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
90%
Hold
10%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,853 2,853
47% 47%
100%
- Direct Costs 1,778 1,778
40% 40%
62%
1,075 1,075
60% 60%
38%
- Selling and Administrative Expenses 498 498
46% 46%
17%
- Research and Development Expense 203 203
65% 65%
7%
625 625
41% 41%
22%
- Depreciation and Amortization 245 245
9% 9%
9%
EBIT (Operating Income) EBIT 380 380
74% 74%
13%
Net Profit 3.38 3.38
104% 104%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
GlobeNewsWire
one day ago
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).
Neutral
GlobeNewsWire
13 days ago
BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal's sodium oxybate oral solution 500 mg/mL Abbreviated New Drug Application (ANDA) which references Jazz Pharmaceuticals' Xyrem®.
Positive
Seeking Alpha
13 days ago
For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future potential drugs. While some profit margins and negative equity could use improvement, the company issued improved guidance for EPS and cashflow.
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today